OncoMatch/Clinical Trials/NCT04920032
Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas
Is NCT04920032 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including TAS-102 and Irinotecan for colon adenocarcinoma.
Treatment: TAS-102 · Irinotecan · Standard Treatment — This is a phase 1b, prospective, single arm, non-randomized, open-label clinical trial determining the efficacy of adjuvant trifluridine and tipiracil (TAS-102) in combination with irinotecan in patients with ctDNA positive colon adenocarcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Colorectal Cancer
Disease stage
Required: Stage II, III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: perioperative chemotherapy — perioperative
after at least 3 months of perioperative chemotherapy
Cannot have received: TAS-102 (TAS-102)
Prior treatment with TAS-102 at any time
Cannot have received: irinotecan (irinotecan)
irinotecan within 90 days from enrollment
Lab requirements
Blood counts
leukocytes ≥ 3,000/mcL; absolute neutrophil count: ≥ 1,500/mcL; platelets: ≥ 80,000/mcl
Kidney function
creatinine: <1.5 X ULN
Liver function
total bilirubin: within normal institutional limits; AST(SGOT)/ALT(SPGT): ≤ 3 X institutional upper limit of normal or ≤ 5 X if liver metastases are present
Adequate organ and marrow function as defined below: 1. leukocytes ≥ 3,000/mcL 2. absolute neutrophil count: ≥ 1,500/mcL 3. platelets: ≥ 80,000/mcl 4. total bilirubin: within normal institutional limits 5. AST(SGOT)/ALT(SPGT): ≤ 3 X institutional upper limit of normal or ≤ 5 X if liver metastases are present 6. creatinine: <1.5 X ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Chao Family Comprehensive Cancer Center, University of California, Irvine · Orange, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04920032 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior TAS-102, irinotecan disqualifies patients from enrollment.
What disease stage is eligible?
Stage II or III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages